Project supported by the National Natural Science Foundation of China (No 30572350, 30170994).
In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik6
Version of Record online: 28 FEB 2007
Acta Pharmacologica Sinica
Volume 28, Issue 3, pages 404–409, March 2007
How to Cite
WU, L.-l., YANG, X.-b., HUANG, Z.-m., LIU, H.-z. and WU, G.-x. (2007), In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik. Acta Pharmacologica Sinica, 28: 404–409. doi: 10.1111/j.1745-7254.2007.00510.x
- Issue online: 28 FEB 2007
- Version of Record online: 28 FEB 2007
- Received 2006-09-28Accepted 2006-10-17
- hepatitis B virus;
- duck hepatitis B virus;
- antiviral agents
Aim: To assess the anti-hepatitis B virus (HBV) effect of hyperoside extracted from Abelmoschus manihot (L) medik. Methods: The human hepatoma Hep G2.2.15 cell culture system and duck hepatitis B virus (DHBV) infection model were used as in vivo and in vitro models to evaluate the anti-HBV effects. Results: In the cell model, the 50% toxic concentration of hyperoside was 0.115 g/L; the maximum nontoxic concentration was 0.05 g/L. On the maximum nontoxic concentrations, the inhibition rates of hyperoside on HBeAg and HBsAg in the 2.2.15 cells were 86.41% and 82.27% on d 8, respectively. In the DHBV infection model, the DHBV-DNA levels decreased significantly in the treatment of 0.05 g- kg-1·d-1 and 0.10 g·kg-1·d-1 dosage groups of hyperoside (P<0.01). The inhibition of the peak of viremia was at the maximum at the dose of 0.10 g-kg-1·d-1 and reached 60.79% on d 10 and 69.78% on d 13, respectively. Conclusion: These results suggested that hyperoside is a strong inhibitor of HBsAg and HBeAg secretion in 2.2.15 cells and DHBV-DNA levels in the HBV-infected duck model.